1stOncology™: Cancer Intelligence Service – Page 7001 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

AACR-2022 NI-2601 & NI-2901 CD47xPD-L1 bispecific antibodies

On April 5, 2022 Light Chain Bioscience reported The American Association for Cancer Research (AACR) (Free AACR Whitepaper) will host its Annual Meeting April 8-13, 2022 (Press release, Light Chain Bioscience, APR 5, 2022, View Source [SID1234611832]). Light Chain Bioscience is very pleased to have Xavier Chauchet attend in-person.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Xavier will be presenting two posters #3225 and #3283 describing differentiating CD47xPD-L1 bispecific #antibody approaches, NI-2601 & NI-2901.

"NI-2601, an Fc-active CD47xPD-L1 bispecific antibody that selectively targets CD47 on PD-L1-positive tumors" (#3283) will be exposed and presented on April 12 between 1:30-5:00 p.m.

↠ Read 1st poster – Poster section 32 [PDF]:

aacr 2022 ni 2901 cd47xpd l1 bispecific antibody for dual immune checkpoint blockade 2601

"NI-2901, a CD47xPD-L1 bispecific antibody for dual immune checkpoint blockade with fine-tuned affinity to reduce erythrocyte binding and improve biodistribution" (#3225) will be exposed and presented on April 12 between 1:30-5:00 p.m.

↠ Read 2nd poster – Poster section 32 [PDF] :

aacr 2022 ni 2901 cd47xpd l1 bispecific antibody for dual immune checkpoint blockade 2901

Ernest N. Morial Convention Center New Orleans, Louisiana

900 Convention Center Blvd, New Orleans, LA 70130, United States

Biogen to Report First Quarter 2022 Financial Results May 3, 2022

On April 5, 2022 Biogen Inc. (Nasdaq:BIIB) reported it will report first quarter 2022 financial results Tuesday, May 3, 2022, before the financial markets open (Press release, Biogen, APR 5, 2022, View Source [SID1234611518]).

Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET. To access the live webcast, please go to the investors section of Biogen’s website at investors.biogen.com. Following the live webcast, an archived version of the call will be available on the website.

TD2 Highlights Two Novel HDAC Inhibitors at AACR Annual Meeting

On April 5, 2022 Translational Drug Development (TD2), a precision oncology contract research organization (CRO), reported the presentation of the preclinical results of two novel, targeted epigenetic inhibitors at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in New Orleans, LA., to be held April 8-13, 2022 (Press release, Research Corporation Tech, APR 5, 2022, View Source [SID1234611500]).

Two posters will be presented at AACR (Free AACR Whitepaper) that discuss the exciting preclinical results from the development of isoform-selective HDAC inhibitors, GB-1101 and GB-3103. The posters will highlight the potential synergies of these HDAC inhibitors with PARP and immune checkpoint inhibitors and the impact on tumor immune microenvironment and tumor progression in models of murine breast, human neuroendocrine prostate, and small cell lung cancers.

"The highly selective HDAC6 inhibitor GB-1101 reprogrammed the tumor immune microenvironment and elicited tumor regressions when combined with checkpoint inhibitors. These data suggest that GB-1101 could be an important new targeted epigenetic immunomodulator able to revoke immune privilege to enhance the clinical activity of immune checkpoint therapies," said Paul Gonzales, Vice President of Nonclinical Operations at TD2. "The potent HDAC3 selective GB-3103 showed broad inhibition of genes in DNA repair pathways and could have utility in enhancing PARP inhibitor activity in homologous repair proficient cancers, or in overcoming PARP inhibitor resistance in homologous repair-deficient tumors."

TD2 will be onsite at AACR (Free AACR Whitepaper) to discuss these important results as well as host an exhibitor booth, #1861.

Abstract 1359: Selective HDAC6 Inhibition By GB-1101 Revokes Tumor Immune Privilege and Synergizes with Immune Checkpoint Therapies to Induce Tumor Regressions (Monday, April 11, 9:00 AM – 12:30 PM CST) Molecular Signaling and Metabolic and Epigenetic Regulation in Adaptive Tumor Immunity Poster Session, Section 37, Poster Board Number 18

Abstract 2607: Inhibition of HDAC3 Induces BRCAness and Potent Synergy with PARP Inhibition in Neuroendocrine Prostate and Small Cell Lung Cancers (Tuesday, April 12, 9:00 AM – 12:30 PM CST) DNA Damage Response and Repair Poster Session, Section 22, Poster Board Number 20

Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022

On April 5, 2022 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported that it will report its first quarter 2022 financial and operating results on Wednesday, May 4, 2022, before the U.S. financial markets open (Press release, Regeneron, APR 5, 2022, View Source [SID1234611493]). The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Conference Call Information
Participants may access the conference call live via webcast on the ‘Investors and Media’ page of Regeneron’s website at View Source To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company’s website for at least 30 days.

Twist Bioscience and Ginkgo Bioworks Sign New Collaboration

On April 5, 2022 Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, reported a new supply agreement expanding the depth and breadth of the collaboration between two of the leading organizations in the synthetic biology ecosystem (Press release, Twist Bioscience, APR 5, 2022, View Source [SID1234611491]). The four-year agreement includes an increased commitment by Ginkgo to purchase products from Twist, with the option to access significantly more synthesis capacity to meet Ginkgo’s anticipated growth. The partnership builds on a previous supply agreement signed in 2017.

"We love to make investments alongside incredible partners like Twist. Over the past four years, we ordered approximately one billion base pairs of synthetic DNA from Twist, allowing us to test hundreds of thousands of proteins across dozens of programs for our customers, resulting in many completed programs spanning vaccine manufacturing, food, flavor, fragrance and even cannabigerol (CBG)," said Jason Kelly, CEO of Ginkgo. "As we grow our capabilities to meet an increasing number and variety of customer needs, we are excited to continue partnering with leading companies in our ecosystem, which includes making sure we secure the high volumes of DNA that Twist is well positioned to supply."

"At Twist, we work in service of our customers, like Ginkgo, who are changing the world for the better," commented Emily M. Leproust, Ph.D., CEO and co-founder of Twist. "Together, Twist and Ginkgo facilitate new product development across multiple industries, with Twist supplying the DNA and Ginkgo programming cells. As the bioeconomy expands with new solutions to the grand challenges facing all of us, we stand ready to deliver day by day, with a vision as to how as an industry, we can truly drive positive outcomes through diverse product solutions."